Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial.

Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial.

Glioblastoma multiforme (GBM) is an aggressive malignancy classified by the World Health Organization as a grade IV glioma. Despite the availability of aggressive standard therapies, most patients experience recurrence, for which there are currently no effective treatments. We aimed to conduct a pha...

Full description

Bibliographic Details
Main Authors: Jaejoon Lim, YoungJoon Park, Ju Won Ahn, JeongMin Sim, Su Jung Kang, Sojung Hwang, Jin Chun, Hyejeong Choi, Sang Heum Kim, Duk-Hee Chun, Kyoung Su Sung, KyuBum Kwack, Kyunggi Cho
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0247293

Internet

https://doi.org/10.1371/journal.pone.0247293

Similar Items